Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
FEBS Lett. 2007 Dec 22;581(30):5897-903. Epub 2007 Dec 3.

Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells.

Author information

  • 1Cardiovascular Research Unit, Department of Medical Science, IRCCS San Raffaele, Rome, Italy.

Erratum in

  • FEBS Lett. 2008 Jan 23;582(2):398. Cauda, Roberto [added]; Lucia, Mothanje Barbara [added].

Abstract

Multi drug resistance (MDR) is defined as the ability of tumor cells to become resistant to unrelated drugs. Tyrosine kinase inhibitor imatinib has been demonstrated to be effective in the treatment of certain tumors. In particular, imatinib inhibits Bcr-Abl kinase activity, c-kit and the phosphorylation of platelet-derived growth factor (PDGF) receptors. In this work, we show that imatinib inhibits PDGF phosphorylation not only in wt Kaposi sarcoma (KS) but also in multi drug resistant KS cells. This was associated with an increased apoptosis in wt cells and an increased autophagy in MDR-KS cells. These data add new insights to the possible use of imatinib in the overcoming of MDR in KS cells.

PMID:
18061581
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk